한빛사논문
- 조회409
Chanjin Yoon 1,2, Yu Seong Ham 1,3, Woo Jin Gil 1,3 and Chul-Su Yang 1,3,4,*
1Department of Molecular and Life Science, Hanyang University, Ansan 15588, South Korea.
2Institute of Natural Science & Technology, Hanyang University, Ansan 15588, South Korea.
3Center for Bionano Intelligence Education and Research, Ansan 15588, South Korea.
4Department of Medicinal and Life Science, Hanyang University, Ansan 15588, South Korea.
*Corresponding author: correspondence to Chul-Su Yang
Abstract
Immune-mediated inflammatory diseases are various groups of conditions that result in immune system disorders and increased cancer risk. Despite the identification of causative cytokines and pathways, current clinical treatment for immune-mediated inflammatory diseases is limited. In addition, immune-mediated inflammatory disease treatment can increase the risk of cancer. Several previous studies have demonstrated that Toxoplasma gondii manipulates the immune response by inhibiting or stimulating cytokines, suggesting the potential for controlling and maintaining a balanced immune system. Additionally, T. gondii also has the unique characteristic of being a so-called “Trojan horse” bacterium that can be used as a drug delivery system to treat regions that have been resistant to previous drug delivery therapies. In this study, we reviewed the potential of T. gondii in drug development and as a delivery system through current research on inflammation-regulating mechanisms in immune-mediated inflammatory diseases.
논문정보
- Review Paper
- 2024년 02월 (BRIC 등록일 2024-02-01)
- 국내 연구진
- 생명과학 > 감염생물학
댓글 작성 로그인
팝업 닫기관련 링크
연구자 키워드
관련분야 연구자보기
소속기관 논문보기
관련분야 논문보기
해당논문 저자보기
